On July 27, Boston Scientific rose 3.08% in regular trading, trading at $45.75 per share, with turnover of approximately $83.68 million. The move comes ahead of the company's quarterly earnings release scheduled for July 29 pre-market, with multiple institutional analysts maintaining bullish ratings.

Market consensus expects Boston Scientific to report revenue of approximately $5.364 billion for the quarter, representing 9.63% year-over-year growth, with adjusted earnings per share of approximately $0.83, up 14.13% year-over-year. On the same day, Oppenheimer trimmed its price target from $90 to $85 but maintained its Outperform rating, with the target remaining significantly above the current stock price. RBC Capital Markets had previously noted that Q2 represents the trough quarter for the year, with growth expected to improve sequentially thereafter, suggesting the market may be pricing in an optimistic earnings outcome ahead of the report.

Boston Scientific develops, manufactures, and markets medical devices across interventional medical specialties worldwide, operating through MedSurg and Cardiovascular segments.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)